(Q47244827)

English

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. (English)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

0 references

circulatory system

1 reference

based on heuristic

inferred from title

Stephan Rössner

1

object named as

Rössner S

1 reference

Europe PubMed Central

12 January 2018

author name string

Sjöström L

2

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

Noack R

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

Meinders AE

4

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

Noseda G

5

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

publication date

1 January 2000

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

8

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

49-61

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

1

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

Body Weight and Mortality among Women

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Actual causes of death in the United States

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Evidence for success of caloric restriction in weight loss and control. Summary of data from industry

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Obesity in Britain: gluttony or sloth?

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Mechanisms of appetite control and their abnormalities in obese patients

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Assessing health-related quality-of-life and health state preference in persons with obesity: a validation study.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

International trial of long-term dexfenfluramine in obesity.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Waist circumference as a measure for indicating need for weight management.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

21 January 2018

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

The influence of dietary fat on food intake and body weight

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2000.8

31 March 2020

Identifiers

10.1038/OBY.2000.8

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/10678259

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47244827&oldid=1610765712"